Academic Highlights: New Developments in Antipsychotic Therapy. [CME]
J Clin Psychiatry 2003;64(11):1379-1390
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Click to enlarge page
W. Wolfgang Fleischhacker, M.D., began the meeting by reviewing the history of the mechanism-based development of antipsychotic drugs. Mechanism-based studies commenced with Paul Janssen’s clinical observation in Belgian cyclists that the dopamine agonist amphetamine led to psychosis and abnormal movements similar to those seen in schizophrenia patients. Expanded knowledge about the pathophysiology of schizophrenia, especially the development and acceptance of the dopamine hypothesis, has also motivated more mechanism-based research.